Guardion Health Sciences (GHSI) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38861
Entity Registrant Name	GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key	0001642375
Entity Tax Identification Number	47-4428421
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2925 Richmond Avenue
Entity Address, Address Line Two	Suite 1200
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77098
City Area Code	800
Local Phone Number	873-5141
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	GHSI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		61,426,993

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash	$ 4,832,469	$ 4,093,927
Short-term investments	11,997,143	4,995,623
Accounts receivable, net	2,198,394	1,411,567
Inventories	822,328	367,691
Prepaid expenses	717,629	1,200,376
Total current assets	20,567,963	12,069,184
Property and equipment, net	94,232	111,378
Intangible assets, net	10,958,333	11,255,833
Operating lease right-of-use asset, net		24,257
Total assets	31,620,528	23,460,652
Current liabilities
Accounts payable	1,146,369	241,347
Accrued expenses	659,401	895,477
Operating lease liability - current	20,638	22,221
Total current liabilities	1,826,408	1,159,045
Operating lease liability – long term		3,807
Total liabilities	1,826,408	1,162,852
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2022 and December 31, 2021
Common stock, $0.001 par value; 250,000,000 shares authorized; 61,426,993 shares and 24,426,993 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	61,427	24,427
Additional paid-in capital	111,153,252	101,075,445
Accumulated deficit	(81,420,559)	(78,802,072)
Total stockholders’ equity	29,794,120	22,297,800
Total liabilities and stockholders’ equity	$ 31,620,528	$ 23,460,652

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	61,426,993	24,426,993
Common stock, shares outstanding	61,426,993	24,426,993

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue
Total revenue	$ 2,384,619	$ 233,297
Cost of goods sold
Total cost of goods sold	1,288,162	133,015
Gross profit	1,096,457	100,282
Operating expenses
Sales and marketing	668,645	457,727
General and administrative	3,016,912	2,291,472
Research and development	6,691	20,608
Impairment of right of use asset	24,257
Total operating expenses	3,716,505	2,769,807
Loss from operations	(2,620,048)	(2,669,525)
Other income (expense)
Interest income	1,561
Total other income (expense)	1,561
Net loss	$ (2,618,487)	$ (2,669,525)
Net loss per common share – basic and diluted	$ (0.07)	$ (0.13)
Weighted average common shares outstanding – basic and diluted	39,150,882	21,351,380
Clinical Nutrition [Member]
Revenue
Total revenue	$ 2,365,900	$ 162,143
Cost of goods sold
Total cost of goods sold	1,288,162	84,917
Diagnostics Equipment [Member]
Revenue
Total revenue	18,719	71,154
Cost of goods sold
Total cost of goods sold		$ 48,098

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 15,171	$ 62,583,423	$ (54,083,328)	$ 8,515,266
Beginning balance, shares at Dec. 31, 2020	15,170,628
Fair value of vested stock options		205,772		205,772
Fair value of vested restricted stock		181,843		181,843
Common stock issued for cash, net of offering costs	$ 7,608	33,654,989		33,662,597
Common stock issued for cash, net of offering costs, shares	7,608,674
Common stock issued upon exercise of warrants	$ 1,648	3,566,767		3,568,415
Common stock issued upon exercise of warrants, shares	1,647,691
Net loss			(2,669,525)	(2,669,525)
Cumulative adjustment due to adoption of ASU 2020-06			25,978	25,978
Ending balance, value at Mar. 31, 2021	$ 24,427	100,192,794	(56,726,875)	43,490,346
Ending balance, shares at Mar. 31, 2021	24,426,993
Beginning balance, value at Dec. 31, 2021	$ 24,427	101,075,445	(78,802,072)	22,297,800
Beginning balance, shares at Dec. 31, 2021	24,426,993
Fair value of vested stock options		85,963		85,963
Fair value of vested restricted stock		59,906		59,906
Common stock issued for cash, net of offering costs	$ 32,550	8,802,349		8,834,899
Common stock issued for cash, net of offering costs, shares	32,550,000
Common stock issued upon exercise of warrants	$ 4,450	1,129,590		1,134,040
Common stock issued upon exercise of warrants, shares	4,450,000
Net loss			(2,618,487)	(2,618,487)
Ending balance, value at Mar. 31, 2022	$ 61,427	$ 111,153,252	$ (81,420,559)	$ 29,794,120
Ending balance, shares at Mar. 31, 2022	61,426,993

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating Activities
Net loss	$ (2,618,487)	$ (2,669,525)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	317,050	19,698
Impairment of operating lease right-of-use asset	24,257
Fair value of vested stock options	85,963	205,772
Fair value of vested restricted common stock	59,906	181,843
(Increase) decrease in:
Accounts receivable	(786,827)	(53,649)
Inventories	(454,637)	96,445
Prepaid expenses	482,746	(132,592)
Operating lease right of use asset		39,470
Increase (decrease) in:
Accounts payable	905,022	(377,910)
Operating lease liability	(5,390)	(39,561)
Accrued expenses	(236,076)	391,189
Payable to former officer		(81,250)
Net cash used in operating activities	(2,226,473)	(2,420,070)
Investing Activities
Purchase of property and equipment	(2,404)
Purchase of US Treasury Bills	(21,977,077)
Sale of US Treasury Bills	14,975,557
Net cash used in investing activities	(7,003,924)
Financing Activities
Proceeds from sale of common stock, net	8,834,899	33,662,597
Proceeds from exercise of warrants	1,134,040	3,568,415
Net cash provided by financing activities	9,968,939	37,231,012
Cash:
Net increase (decrease)	738,542	34,810,942
Balance at beginning of period	4,093,927	8,518,732
Balance at end of period	4,832,469	43,329,674
Cash paid for:
Interest
Income taxes

Organization and Business Opera

Organization and Business Operations	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Business Guardion Health Sciences, Inc. (the “Company”) is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support healthcare professionals and providers and their patients, and consumers. In June 2021, the Company acquired Activ Nutritional, LLC (“Activ”), the owner and distributor of the Viactiv® line of supplements for bone health and other applications (see Note 3). The acquisition significantly changed the operations of the Company, and the integration of the Viactiv line of products has materially changed the Company’s financial position and operating focus. Liquidity The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. For the three months ended March 31, 2022, the Company incurred a net loss of $ 2,618,487 2,226,473 16,829,612 18,741,555 Notwithstanding the net loss for the three months ended March 31, 2022, management believes that its current cash and short-term investments as of March 31, 2022 are sufficient to ensure continuation of the Company as a going concern for at least one year from the date of this quarterly report. The amount and timing of future cash requirements will depend, in part, on the Company’s ability to ultimately achieve operating profitability. The Company expects to continue to incur net losses and negative operating cash flows in the near-term and will continue to incur significant expenses for the development, commercialization and distribution of its clinical nutrition products and the successful development and commercialization of any new products or product lines. The Company may also utilize cash to fund additional acquisitions or other strategic initiatives. The Company may seek to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms, or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its product development programs and/or curtail or cease its operations. COVID-19 The Company is subject to risks and uncertainties from the COVID-19 pandemic that could adversely impact the Company’s business. The Company has implemented health and safety precautions and protocols in response to the pandemic and government guidelines. The Company’s financial results for the three months ended March 31, 2022 have been affected by supply chain constraints due, in large part, to the COVID-19 pandemic. These constraints began in the fourth quarter of 2021 and have continued into 2022 and have impacted the Company’s ability to obtain inventory to fulfill customer orders for its Viactiv branded products and may continue to impact the Company’s ability to fulfill customer orders going forward which may have a material adverse effect on the Company’s business and results of operations. The Company continues to experience some challenges to meet customer demands, largely because of shortages in the Company’s suppliers’ labor, which negatively impacts the availability of many critical components in the Company’s supply chain and distribution. Additionally, the Company is subject to out-of-stock fees to certain retailers in the event that it is unable to adequately maintain certain inventory levels of its Viactiv products with such retailers. Although the Company expects these supply chain challenges to continue through approximately the third quarter of 2022, the Company has begun to see some improvement in the inventory production cycle. Additionally, the Company and its suppliers are experiencing significant broad-based inflation of manufacturing and distribution costs as well as transportation challenges, partially as a result of the pandemic. The Company expects input cost inflation to continue at least throughout 2022.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures have been condensed or omitted pursuant to the rules and regulations of the SEC. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the fiscal year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K, as filed with the SEC on March 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. The Company’s unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair presentation of the periods presented. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2022. For the year ended December 31, 2021, management concluded that the Company has one operating and reporting segment made up of its clinical nutrition business, and management changed the Company’s reportable segments to align with these revisions to the Company’s internal reporting structure. The Company previously had two reportable segments, which included a clinical nutrition segment and a medical devices segment. At March 31, 2022 and December 31, 2021, as there was only one reporting unit, all of the Company’s prior period segment information has been eliminated. Reverse Stock Split On March 1, 2021, the Company effectuated a one-for-six (1:6) reverse stock split Use of Estimates The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. On an ongoing basis, management reviews its estimates and, if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ from those estimates. Revenue Recognition In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, Historically, the Company has not experienced any significant payment delays from customers. Due to the insignificant amount of historical returns, as well as the standalone nature of the Company’s products, and the assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. Revenues by geographical area are as follows: Schedule of Revenue by Geographical Area 2022 2021 Three Months Ended 2022 2021 North America $ 2,365,720 $ 172,140 Asia - 58,262 Europe and Other 18,899 2,895 Total revenue $ 2,384,619 $ 233,297 Third-Party Outsourcing The Company derives substantially all of its revenue from the sale of products using a third-party fulfillment center to provide order processing and sales fulfillment, customer invoicing and collections, and product warehousing. Substantially all of the Company’s products are shipped through the third-party fulfillment center to the customer. Shipping charges to customers are included in revenues. In addition, the Company uses the third-party fulfillment center to provide sales and inventory management, and marketing and promotional services. The Company outsources the production of substantially all of its products with a third party that manufactures and packages the finished products under a product supply agreement. For the three months ended March 31, 2022, costs incurred related to third-party outsourcing which includes manufacturing, order processing and fulfillment, customer invoicing, collections and warehousing, were approximately $ 1,847,000 Cost of Goods Sold Cost of goods sold is comprised of the costs for third-party contract manufacturing, packaging, manufacturing fees, and in-bound freight charges. Shipping Costs Shipping costs associated with product distribution after manufacture are included as part of cost of goods sold. Shipping and handling expense totaled $ 135,423 17,474 Advertising Costs Advertising costs are expensed as incurred and are included in sales and marketing expense. Advertising costs were $ 587,361 44,429 Concentrations Revenue. 59 % of total revenue. During the three months ended March 31, 2021, the Company had one customer that accounted for 25 % of the Company’s total revenue. No other customer accounted for more than 10 % of revenue , Accounts receivable March 31, 2022 , the Company had accounts receivable from one customer which comprised approximately 51 , the Company had accounts receivable from two customers which comprised approximately 50 48 10 and 2021. Purchases from vendors three months ended March 31, 2022 , the Company utilized one manufacturer for most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately 41 15 13 , the Company’s largest vendor accounted for approximately 38 10 and 2021. Accounts payable March 31, 2022 , one vendor accounted for 87 the Company’s largest two vendors accounted for 18 13 10 and 2021. Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. Stock option grants, which are generally time or performance vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. Loss per Common Share Basic loss per share is computed by dividing net loss by the weighted-average common shares outstanding during the period, excluding shares of unvested restricted common stock. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Dilutive potential common shares include shares from unexercised warrants and options. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. The Company’s basic and diluted net loss per share is the same for all periods presented as the Company had a net loss for all periods presented and all shares issuable upon exercise of warrants and options would therefore be anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share March 31, 2022 2021 Warrants 74,485,067 485,067 Options 853,088 930,867 Unvested restricted common stock 50,000 152,671 Anti-dilutive securities excluded from computation of earnings per share 75,388,155 1,568,605 Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1 - Level 2 - Level 3 - The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The following table sets forth by level, within the fair value hierarchy, the Company’s financial assets at fair value as of March 31, 2022 and December 31, 2021: Schedule of Financial Assets at Fair Value Level 1 Level 2 Level 3 Total March 31, 2022 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ 11,997,143 $ - $ - $ 11,997,143 Total assets $ 11,997,143 $ - $ - $ 11,997,143 Level 1 Level 2 Level 3 Total December 31, 2021 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ 4,995,623 - - 4,995,623 Total assets $ 4,995,623 $ - $ - $ 4,995,623 The Company believes the carrying amount of its financial instruments (consisting of cash, short-term investments, accounts receivable, accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) . At December 31, 2020, the Company recorded a derivative liability of $ 25,978 10,417 25,978 25,978 In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows. Other recent accounting pronouncements issued by FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Acquisition of Activ Nutritiona

Acquisition of Activ Nutritional, LLC	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisition of Activ Nutritional, LLC	3. Acquisition of Activ Nutritional, LLC In June 2021, the Company acquired Activ, the owner and distributor of the Viactiv® line of supplements for bone health and other applications, for total purchase consideration of $ 25,949,654 The following table summarizes the allocation of the fair value of the purchase consideration to the fair value of tangible assets, identifiable intangible assets, and assumed liabilities of Activ on the date of acquisition: Schedule of Fair Value of Assets Acquired and Liabilities Assumed Fair value of consideration: Purchase price, as adjusted, paid in cash $ 25,949,654 Allocation of the consideration to the fair value of assets acquired and liabilities assumed: Cash $ 8,468 Accounts receivable 1,799,695 Inventories 613,063 Prepaids 49,025 Accounts payable (313,731 ) Net tangible assets 2,156,520 Trade names and trademarks 9,200,000 Customer relationships 2,700,000 Net identifiable intangible assets 11,900,000 Goodwill 11,893,134 Fair value of net assets acquired $ 25,949,654 The Company consolidated Activ’s operations with the Company’s operations commencing on June 1, 2021. The Company performed a goodwill impairment test as of December 31, 2021, and based on the result, goodwill was determined to be impaired. Accordingly, goodwill of $ 11,893,134 During the three months ended March 31, 2022, the amount of revenue and net loss of Activ included in the Company’s condensed consolidated statements of operations was $ 2,259,631 209,830 Pro Forma Information The following unaudited pro forma condensed consolidated statement of operations for the three months ended March 31, 2021 is presented as if the acquisition of Activ had occurred on January 1, 2021, after giving effect to certain pro forma adjustments. The pro forma results of operations are presented for informational purposes only and are not indicative of the results of operations that would have been achieved if the acquisition had actually been consummated on January 1, 2021. These results are prepared in accordance with ASC 606. Schedule of Pro Forma Financial Information March 31 2021 Revenue $ 3,973,716 Net loss $ (2,031,155 ) Net loss per share – basic and diluted $ (0.09 ) Acquisition-related transaction costs (e.g., legal, due diligence, valuation, investment banking and other professional fees) are not included as a component of consideration transferred but were expensed as incurred. During the three months ended March 31, 2022 and 2021, the Company incurred no acquisition-related costs

Inventories

Inventories	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories consisted of the following: Schedule of Inventories March 31, December 31, 2022 2021 Raw materials $ 45,988 $ 53,320 Finished goods 776,340 314,371 Inventory $ 822,328 $ 367,691 The Company’s inventories are stated at the lower of cost or net realizable value calculated on a first in first out basis.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net consisted of the following: Schedule of Property and Equipment March 31, December 31, 2022 2021 Furniture and fixtures $ 110,176 $ 129,696 Computer equipment and software 113,873 111,469 Other - 6,540 Property plant and equipment gross 224,049 247,705 Less accumulated depreciation and amortization (129,817 ) (136,327 ) Property plant and equipment net $ 94,232 $ 111,378 Depreciation expense for the three months ended March 31, 2022 and 2021 was $ 19,550 19,698 26,060 26,060

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	6. Intangible Assets, Net Intangible assets, net consisted of the following: Schedule of Intangible Assets March 31, December 31, 2022 2021 Trade name $ 9,200,000 $ 9,200,000 Customer relationships 2,700,000 2,700,000 Trademark 50,000 50,000 Intangible assets, gross 11,950,000 11,950,000 Less accumulated amortization (991,667 ) (694,167 ) Intangible assets, net $ 10,958,333 $ 11,255,833 Amortizable finite-lived identifiable intangible assets consist of a trade name and customer relationships acquired in the acquisition of Activ, effective as of June 1, 2021 (See Note 3) and are being amortized over a period of 10 50,000 For the three months ended March 31, 2022, amortization expense was $ 297,500 Schedule of Finite-lived Intangible Assets Amortization Expense Total 2022 (remaining 9 months) $ 892,500 2023 1,190,000 2024 1,190,000 2025 1,190,000 2026 1,190,000 Thereafter 5,255,833 Total future expected amortization expense $ 10,908,333

Operating Leases

Operating Leases	3 Months Ended
	Mar. 31, 2022
Operating Leases
Operating Leases	7. Operating Leases At March 31, 2022, the Company leases its primary corporate office space located in Houston, Texas, under a month-to-month lease with lease payments of approximately $ 1,700 During the three months ended March 31, 2022 and 2021, rent expense totaled $ 11,634 45,901 As of December 31, 2021, the Company’s right of use asset related to its warehouse space totaled $ 24,257 24,257 0 As of December 31, 2021, the Company’s operating lease liability related to its warehouse space totaled $ 26,028 5,390 20,638 As of March 31, 2022, the remaining lease term related to the warehouse space is 11 months, and the discount rate for the warehouse space operating lease is 3.9 Future minimum lease payments under the leases are as follows: Schedule of Lease Liability Year ending Operating Lease 2022 (remaining 9 months) $ 17,217 2023 3,826 Total lease payments 21,043 Less: Imputed interest/present value discount (405 ) Present value of lease liabilities 20,638 Less: Current portion (20,638 ) Operating Lease Liability Noncurrent $ -

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Equity	8. Stockholders’ Equity Common Stock February 2022 Offering On February 18, 2022, the Company, entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company sold (i) 32,550,000 shares of common stock, (ii) Series A Warrants to purchase 37,000,000 shares of common stock, (iii) Series B Warrants to purchase 37,000,000 shares of common stock and (iv) Pre-Funded Warrants to purchase 4,450,000 shares of common stock. On February 23, 2022, the offering closed, generating gross proceeds of $ 11,100,000 9,969,000 . Included in the offering were net proceeds of approximately $ 1,134,000 from the exercise of warrants. In the event that the Company fails to deliver shares by the required delivery date upon exercise of the warrants, the Company may be subject to cash penalties in an amount equal to up to $ 20 per trading day for each $ 1,000 of warrant shares until such shares are delivered. In addition, if the warrant holder purchases shares in the market following the Company’s failure to deliver shares upon exercise of the warrants, the Company will be required to cover the cost of any buy-ins and, at the option of the warrant holder, either reinstate the portion of the warrant for the shares that were not delivered or deliver the number of shares that should have been issued. January 2021 and February 2021 At the Market Offerings On January 8, 2021, the Company entered into a sales agreement with Maxim Group LLC (“Maxim”) pursuant to which the Company could sell up to $ 10,000,000 2,559,834 9,700,000 On January 28, 2021, the Company entered into a sales agreement with Maxim pursuant to which the Company could sell up to $ 25,000,000 5,048,840 24,250,000 The Company incurred costs related to these financings of approximately $ 327,000 which is reflected as a reduction to the proceeds from the shares issued. The net cash received from the January 2021 ATM Offerings was approximately $ 33,663,000 , after deducting all offering expenses. Warrants A summary of the Company’s warrant activity is as follows: Schedule of Warrants Activity Shares Weighted Weighted December 31, 2021 485,067 $ 2.71 2.71 Granted 78,450,000 0.37 3.25 Forfeitures - - - Expirations - - - Exercised (4,450,000 ) - - March 31, 2022, all exercisable 74,485,067 $ 0.38 3.24 The exercise prices of warrants outstanding and exercisable as of March 31, 2022 are as follows: Schedule of Exercise Price of Warrants Outstanding and Exercisable Warrants Outstanding and Exercise Prices 74,000,000 $ 0.37 160,108 2.05 146,667 2.67 112,001 3.30 37,700 3.51 18,174 17.25 10,417 30.00 74,485,067 During the three months ended March 31, 2022, investors exercised warrants to purchase 4,450,000 0.2999 1,334,555 Stock Options A summary of the Company’s stock option activity is as follows: Schedule of Share-based Compensation, Stock Options, Activity Shares Weighted Weighted December 31, 2021 853,088 $ 6.34 6.5 Granted - - - Forfeitures - - - Expirations - - - Exercised - - - March 31, 2022, outstanding 853,088 $ 6.34 6.25 March 31, 2022, exercisable 636,259 $ 7.41 4.95 The exercise prices of options outstanding and exercisable as of March 31, 2022 are as follows: Schedule of Exercise Price of Options Outstanding and Exercisable Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 41,667 23,347 $ 0.91 41,667 41,667 1.48 50,000 - 1.61 66,668 24,996 1.76 5,000 5,000 1.91 41,667 41,667 2.33 1,667 1,667 2.46 16,667 12,501 3.25 152,671 59,373 3.95 208,333 208,333 6.00 104,167 104,167 12.00 10,414 1,041 13.80 112,500 112,500 15.00 853,088 636,259 During the three months ended March 31, 2022, there were no grants of options to purchase shares of common stock. During the three months ended March 31, 2021, the Company granted options to purchase 152,671 514,171 119 0.38 zero 6 3.95 50,891 one two years The Company computes stock price volatility over expected terms based on its historical common stock trading prices. The risk-free interest rate was based on rates established by the Federal Reserve Bank. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future. The expected life of the stock options granted is estimated using the “simplified” method, whereby the expected term equals the average of the vesting term and the original contractual term of the stock option. For the three months ended March 31, 2022 and 2021, the Company recognized aggregate stock-compensation expense of $ 85,963 205,772 As of March 31, 2022, the Company had an aggregate of 216,829 284,388 5.2 0.23 0 Restricted Common Stock During the three months ended March 31, 2022, there were no grants of restricted common stock. During the three-months ended March 31, 2021, the Company granted 152,671 41,667 The total fair value of the 194,338 662,412 59,906 181,843 41,925 2.25 The following table summarizes restricted common stock activity for the three months ended March 31, 2022: Schedule of Non Vested Restricted Common Stock Activity Number of shares Fair value of shares Non-vested shares, December 31, 2021 202,671 $ 3.38 Granted - - Vested (152,671 ) 3.95 Forfeited - - Non-vested shares, March 31, 2022 50,000 $ 1.61 2018 Equity Incentive Plan In 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (as amended, the “2018 Plan”). Under the 2018 Plan, up to 1,666,667 shares of common stock may be granted to employees, directors and consultants in the form of stock options, restricted stock units and other stock-based awards . The terms of awards granted under the 2018 Plan are determined by the Compensation Committee of the Board of Directors, subject to the provisions of the 2018 Plan. Options granted under the 2018 Plan expire depending on the individual terms of each grant. The vesting of stock options and restricted stock units granted under the 2018 Plan is variable based on the individual terms of each individual grant. During the three months ended March 31, 2022 and 2021, there were no stock options, restricted stock units and other stock-based awards issued under the 2018 Plan. As of March 31, 2022, the Company has granted 626,006 stock options and 202,671 shares of restricted common stock under the 2018 Plan. As of March 31, 2022, there was a balance of 837,990 shares of common stock available for grants under the 2018 Plan.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies In the normal course of business, the Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations. In the opinion of management, adequate provision has been made in the Company’s financial statements at March 31, 2022 and December 31, 2021 with respect to any such matters. The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against the Company that it believes could have a material adverse effect on its business, operating results, cash flows or financial condition. Nasdaq Notice On January 25, 2022, the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of $ 1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(3)(A), the Company is provided a compliance period of 180 calendar days from the date of the Notice, or until July 25, 2022, to regain compliance with the minimum closing bid price requirement. If the Company does not regain compliance during the compliance period ending July 25, 2022, the Company may request that Nasdaq grant the Company a second 180 calendar day period to regain compliance. To qualify for the second compliance period, the Company must (i) meet the continued listing requirement for The Nasdaq Capital Market, with the exception of the bid price requirement, and (ii) notify Nasdaq of its intent to cure the deficiency during the second compliance period. No assurance can be provided that the Company would be granted a second 180 calendar day period to regain compliance. To regain compliance, the bid price of the Company’s common stock must have a closing bid price of 1.00 The Company plans to carefully assess potential actions to regain compliance. However, the Company may be unable to regain compliance with the minimum closing bid price requirement during the compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events The Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC. There were no material subsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures have been condensed or omitted pursuant to the rules and regulations of the SEC. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the fiscal year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K, as filed with the SEC on March 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. The Company’s unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair presentation of the periods presented. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2022. For the year ended December 31, 2021, management concluded that the Company has one operating and reporting segment made up of its clinical nutrition business, and management changed the Company’s reportable segments to align with these revisions to the Company’s internal reporting structure. The Company previously had two reportable segments, which included a clinical nutrition segment and a medical devices segment. At March 31, 2022 and December 31, 2021, as there was only one reporting unit, all of the Company’s prior period segment information has been eliminated.
Reverse Stock Split	Reverse Stock Split On March 1, 2021, the Company effectuated a one-for-six (1:6) reverse stock split
Use of Estimates	Use of Estimates The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. On an ongoing basis, management reviews its estimates and, if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, Historically, the Company has not experienced any significant payment delays from customers. Due to the insignificant amount of historical returns, as well as the standalone nature of the Company’s products, and the assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. Revenues by geographical area are as follows: Schedule of Revenue by Geographical Area 2022 2021 Three Months Ended 2022 2021 North America $ 2,365,720 $ 172,140 Asia - 58,262 Europe and Other 18,899 2,895 Total revenue $ 2,384,619 $ 233,297 Third-Party Outsourcing The Company derives substantially all of its revenue from the sale of products using a third-party fulfillment center to provide order processing and sales fulfillment, customer invoicing and collections, and product warehousing. Substantially all of the Company’s products are shipped through the third-party fulfillment center to the customer. Shipping charges to customers are included in revenues. In addition, the Company uses the third-party fulfillment center to provide sales and inventory management, and marketing and promotional services. The Company outsources the production of substantially all of its products with a third party that manufactures and packages the finished products under a product supply agreement. For the three months ended March 31, 2022, costs incurred related to third-party outsourcing which includes manufacturing, order processing and fulfillment, customer invoicing, collections and warehousing, were approximately $ 1,847,000
Cost of Goods Sold	Cost of Goods Sold Cost of goods sold is comprised of the costs for third-party contract manufacturing, packaging, manufacturing fees, and in-bound freight charges.
Shipping Costs	Shipping Costs Shipping costs associated with product distribution after manufacture are included as part of cost of goods sold. Shipping and handling expense totaled $ 135,423 17,474
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and are included in sales and marketing expense. Advertising costs were $ 587,361 44,429
Concentrations	Concentrations Revenue. 59 % of total revenue. During the three months ended March 31, 2021, the Company had one customer that accounted for 25 % of the Company’s total revenue. No other customer accounted for more than 10 % of revenue , Accounts receivable March 31, 2022 , the Company had accounts receivable from one customer which comprised approximately 51 , the Company had accounts receivable from two customers which comprised approximately 50 48 10 and 2021. Purchases from vendors three months ended March 31, 2022 , the Company utilized one manufacturer for most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately 41 15 13 , the Company’s largest vendor accounted for approximately 38 10 and 2021. Accounts payable March 31, 2022 , one vendor accounted for 87 the Company’s largest two vendors accounted for 18 13 10 and 2021.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. Stock option grants, which are generally time or performance vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.
Loss per Common Share	Loss per Common Share Basic loss per share is computed by dividing net loss by the weighted-average common shares outstanding during the period, excluding shares of unvested restricted common stock. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Dilutive potential common shares include shares from unexercised warrants and options. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. The Company’s basic and diluted net loss per share is the same for all periods presented as the Company had a net loss for all periods presented and all shares issuable upon exercise of warrants and options would therefore be anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share March 31, 2022 2021 Warrants 74,485,067 485,067 Options 853,088 930,867 Unvested restricted common stock 50,000 152,671 Anti-dilutive securities excluded from computation of earnings per share 75,388,155 1,568,605
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1 - Level 2 - Level 3 - The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The following table sets forth by level, within the fair value hierarchy, the Company’s financial assets at fair value as of March 31, 2022 and December 31, 2021: Schedule of Financial Assets at Fair Value Level 1 Level 2 Level 3 Total March 31, 2022 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ 11,997,143 $ - $ - $ 11,997,143 Total assets $ 11,997,143 $ - $ - $ 11,997,143 Level 1 Level 2 Level 3 Total December 31, 2021 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ 4,995,623 - - 4,995,623 Total assets $ 4,995,623 $ - $ - $ 4,995,623 The Company believes the carrying amount of its financial instruments (consisting of cash, short-term investments, accounts receivable, accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) . At December 31, 2020, the Company recorded a derivative liability of $ 25,978 10,417 25,978 25,978 In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows. Other recent accounting pronouncements issued by FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Revenue by Geographical Area	Revenues by geographical area are as follows: Schedule of Revenue by Geographical Area 2022 2021 Three Months Ended 2022 2021 North America $ 2,365,720 $ 172,140 Asia - 58,262 Europe and Other 18,899 2,895 Total revenue $ 2,384,619 $ 233,297
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share March 31, 2022 2021 Warrants 74,485,067 485,067 Options 853,088 930,867 Unvested restricted common stock 50,000 152,671 Anti-dilutive securities excluded from computation of earnings per share 75,388,155 1,568,605
Schedule of Financial Assets at Fair Value	The following table sets forth by level, within the fair value hierarchy, the Company’s financial assets at fair value as of March 31, 2022 and December 31, 2021: Schedule of Financial Assets at Fair Value Level 1 Level 2 Level 3 Total March 31, 2022 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ 11,997,143 $ - $ - $ 11,997,143 Total assets $ 11,997,143 $ - $ - $ 11,997,143 Level 1 Level 2 Level 3 Total December 31, 2021 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ 4,995,623 - - 4,995,623 Total assets $ 4,995,623 $ - $ - $ 4,995,623

Acquisition of Activ Nutritio_2

Acquisition of Activ Nutritional, LLC (Tables)	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the fair value of the purchase consideration to the fair value of tangible assets, identifiable intangible assets, and assumed liabilities of Activ on the date of acquisition: Schedule of Fair Value of Assets Acquired and Liabilities Assumed Fair value of consideration: Purchase price, as adjusted, paid in cash $ 25,949,654 Allocation of the consideration to the fair value of assets acquired and liabilities assumed: Cash $ 8,468 Accounts receivable 1,799,695 Inventories 613,063 Prepaids 49,025 Accounts payable (313,731 ) Net tangible assets 2,156,520 Trade names and trademarks 9,200,000 Customer relationships 2,700,000 Net identifiable intangible assets 11,900,000 Goodwill 11,893,134 Fair value of net assets acquired $ 25,949,654
Schedule of Pro Forma Financial Information	Schedule of Pro Forma Financial Information March 31 2021 Revenue $ 3,973,716 Net loss $ (2,031,155 ) Net loss per share – basic and diluted $ (0.09 )

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following: Schedule of Inventories March 31, December 31, 2022 2021 Raw materials $ 45,988 $ 53,320 Finished goods 776,340 314,371 Inventory $ 822,328 $ 367,691

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consisted of the following: Schedule of Property and Equipment March 31, December 31, 2022 2021 Furniture and fixtures $ 110,176 $ 129,696 Computer equipment and software 113,873 111,469 Other - 6,540 Property plant and equipment gross 224,049 247,705 Less accumulated depreciation and amortization (129,817 ) (136,327 ) Property plant and equipment net $ 94,232 $ 111,378

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets, net consisted of the following: Schedule of Intangible Assets March 31, December 31, 2022 2021 Trade name $ 9,200,000 $ 9,200,000 Customer relationships 2,700,000 2,700,000 Trademark 50,000 50,000 Intangible assets, gross 11,950,000 11,950,000 Less accumulated amortization (991,667 ) (694,167 ) Intangible assets, net $ 10,958,333 $ 11,255,833
Schedule of Finite-lived Intangible Assets Amortization Expense	Schedule of Finite-lived Intangible Assets Amortization Expense Total 2022 (remaining 9 months) $ 892,500 2023 1,190,000 2024 1,190,000 2025 1,190,000 2026 1,190,000 Thereafter 5,255,833 Total future expected amortization expense $ 10,908,333

Operating Leases (Tables)

Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Operating Leases
Schedule of Lease Liability	Future minimum lease payments under the leases are as follows: Schedule of Lease Liability Year ending Operating Lease 2022 (remaining 9 months) $ 17,217 2023 3,826 Total lease payments 21,043 Less: Imputed interest/present value discount (405 ) Present value of lease liabilities 20,638 Less: Current portion (20,638 ) Operating Lease Liability Noncurrent $ -

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Warrants Activity	A summary of the Company’s warrant activity is as follows: Schedule of Warrants Activity Shares Weighted Weighted December 31, 2021 485,067 $ 2.71 2.71 Granted 78,450,000 0.37 3.25 Forfeitures - - - Expirations - - - Exercised (4,450,000 ) - - March 31, 2022, all exercisable 74,485,067 $ 0.38 3.24
Schedule of Exercise Price of Warrants Outstanding and Exercisable	The exercise prices of warrants outstanding and exercisable as of March 31, 2022 are as follows: Schedule of Exercise Price of Warrants Outstanding and Exercisable Warrants Outstanding and Exercise Prices 74,000,000 $ 0.37 160,108 2.05 146,667 2.67 112,001 3.30 37,700 3.51 18,174 17.25 10,417 30.00 74,485,067
Schedule of Share-based Compensation, Stock Options, Activity	A summary of the Company’s stock option activity is as follows: Schedule of Share-based Compensation, Stock Options, Activity Shares Weighted Weighted December 31, 2021 853,088 $ 6.34 6.5 Granted - - - Forfeitures - - - Expirations - - - Exercised - - - March 31, 2022, outstanding 853,088 $ 6.34 6.25 March 31, 2022, exercisable 636,259 $ 7.41 4.95
Schedule of Exercise Price of Options Outstanding and Exercisable	The exercise prices of options outstanding and exercisable as of March 31, 2022 are as follows: Schedule of Exercise Price of Options Outstanding and Exercisable Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 41,667 23,347 $ 0.91 41,667 41,667 1.48 50,000 - 1.61 66,668 24,996 1.76 5,000 5,000 1.91 41,667 41,667 2.33 1,667 1,667 2.46 16,667 12,501 3.25 152,671 59,373 3.95 208,333 208,333 6.00 104,167 104,167 12.00 10,414 1,041 13.80 112,500 112,500 15.00 853,088 636,259
Schedule of Non Vested Restricted Common Stock Activity	The following table summarizes restricted common stock activity for the three months ended March 31, 2022: Schedule of Non Vested Restricted Common Stock Activity Number of shares Fair value of shares Non-vested shares, December 31, 2021 202,671 $ 3.38 Granted - - Vested (152,671 ) 3.95 Forfeited - - Non-vested shares, March 31, 2022 50,000 $ 1.61

Organization and Business Ope_2

Organization and Business Operations (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income Loss	$ 2,618,487	$ 2,669,525
Net cash used in operating activities	2,226,473	$ 2,420,070
Cash and short-term investments	16,829,612
Working capital	$ 18,741,555

Schedule of Revenue by Geograph

Schedule of Revenue by Geographical Area (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total revenue	$ 2,384,619	$ 233,297
North America [Member]
Total revenue	2,365,720	172,140
Asia [Member]
Total revenue		58,262
Europe and Other [Member]
Total revenue	$ 18,899	$ 2,895

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	75,388,155	1,568,605
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	74,485,067	485,067
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	853,088	930,867
Unvested Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	50,000	152,671

Schedule of Financial Assets at

Schedule of Financial Assets at Fair Value (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Total assets	$ 11,997,143	$ 4,995,623
US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets	11,997,143	4,995,623
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets	11,997,143	4,995,623
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets	11,997,143	4,995,623
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	Mar. 01, 2021	Mar. 31, 2022USD ($)Segment	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)Segment	Dec. 31, 2020USD ($)	Dec. 31, 2019shares
Product Information [Line Items]
Number of Reporting Units | Segment		1		2
Stockholders' Equity, Reverse Stock Split	one-for-six (1:6) reverse stock split
Third party outsourcing		$ 1,847,000
Cost of goods sold		1,288,162	$ 133,015
Advertising costs		587,361	$ 44,429
Derivative liability					$ 25,978
Accumulated deficit		$ 81,420,559		$ 78,802,072
Accounting Standards Update 2020-06 [Member]
Product Information [Line Items]
Accumulated deficit					25,978
Decrease in derivative warrant liability					$ 25,978
Warrant [Member]
Product Information [Line Items]
Number of warrants issued | shares						10,417
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration Risk, Percentage		59.00%	25.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Other Customers [Member] | Minimum [Member]
Product Information [Line Items]
Concentration Risk, Percentage		10.00%	10.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration Risk, Percentage		51.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Other Customers [Member] | Minimum [Member]
Product Information [Line Items]
Concentration Risk, Percentage		10.00%	10.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage				50.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration Risk, Percentage				48.00%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage		15.00%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration Risk, Percentage		13.00%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | One Manufacturer [Member]
Product Information [Line Items]
Concentration Risk, Percentage		41.00%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Vendor [Member]
Product Information [Line Items]
Concentration Risk, Percentage			38.00%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Other Vendor [Member] | Minimum [Member]
Product Information [Line Items]
Concentration Risk, Percentage		10.00%	10.00%
Accounts Payable [Member] | Customer Concentration Risk [Member] | Other Vendor [Member] | Minimum [Member]
Product Information [Line Items]
Concentration Risk, Percentage		10.00%	10.00%
Accounts Payable [Member] | Customer Concentration Risk [Member] | One Vendor [Member]
Product Information [Line Items]
Concentration Risk, Percentage		87.00%
Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor One [Member]
Product Information [Line Items]
Concentration Risk, Percentage				18.00%
Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor Two [Member]
Product Information [Line Items]
Concentration Risk, Percentage				13.00%
Shipping and Handling [Member]
Product Information [Line Items]
Cost of goods sold		$ 135,423	$ 17,474

Schedule of Fair Value of Asset

Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details) - Activ Nutritional, LLC [Member]	Jun. 01, 2021USD ($)
Business Acquisition [Line Items]
Purchase price, as adjusted, paid in cash	$ 25,949,654
Cash	8,468
Accounts receivables	1,799,695
Inventories	613,063
Prepaids	49,025
Accounts Payable	(313,731)
Net tangible assets	2,156,520
Net identifiable intangible assets	11,900,000
Goodwill	11,893,134
Fair value of net assets acquired	25,949,654
Trademarks [Member]
Business Acquisition [Line Items]
Net identifiable intangible assets	9,200,000
Customer Relationships [Member]
Business Acquisition [Line Items]
Net identifiable intangible assets	$ 2,700,000

Schedule of Pro Forma Financial

Schedule of Pro Forma Financial Information (Details)	3 Months Ended
	Mar. 31, 2021USD ($)$ / shares
Business Combination and Asset Acquisition [Abstract]
Revenue	$ 3,973,716
Net loss	$ (2,031,155)
Net loss per share – basic and diluted | $ / shares	$ (0.09)

Acquisition of Activ Nutritio_3

Acquisition of Activ Nutritional, LLC (Details Narrative) - USD ($)	Jun. 01, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue		$ 2,384,619	$ 233,297
Net Income Loss		(2,618,487)	$ (2,669,525)
Activ Nutritional, LLC [Member]
Purchase consideration	$ 25,949,654
Goodwill				$ 11,893,134
Revenue		2,259,631
Net Income Loss		$ 209,830

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 45,988	$ 53,320
Finished goods	776,340	314,371
Inventory	$ 822,328	$ 367,691

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 224,049	$ 247,705
Less accumulated depreciation and amortization	(129,817)	(136,327)
Property, Plant and Equipment, Net	94,232	111,378
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	110,176	129,696
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	113,873	111,469
Other [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		$ 6,540

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation and Amortization	$ 19,550	$ 19,698
Cost of depreciated assets	26,060
Removal of depreciation	$ 26,060

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Trade name	$ 9,200,000	$ 9,200,000
Customer relationships	2,700,000	2,700,000
Trademark	50,000	50,000
Intangible assets, gross	11,950,000	11,950,000
Less accumulated amortization	(991,667)	(694,167)
Intangible assets, net	$ 10,958,333	$ 11,255,833

Schedule of Finite-lived Intang

Schedule of Finite-lived Intangible Assets Amortization Expense (Details)	Mar. 31, 2022USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (remaining 9 months)	$ 892,500
2023	1,190,000
2024	1,190,000
2025	1,190,000
2026	1,190,000
Thereafter	5,255,833
Total future expected amortization expense	$ 10,908,333

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative) - USD ($)	Jun. 01, 2021	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization period	10 years
Indefinite-lived intangible asset		$ 50,000	$ 50,000
Amortization of Intangible Assets		$ 297,500

Schedule of Lease Liability (De

Schedule of Lease Liability (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Operating Leases
2022 (remaining 9 months)	$ 17,217
2023	3,826
Total lease payments	21,043
Less: Imputed interest/present value discount	(405)
Present value of lease liabilities	20,638	$ 26,028
Less: Current portion	(20,638)	(22,221)
Operating Lease Liability Noncurrent		$ 3,807

Operating Leases (Details Narra

Operating Leases (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Operating Leases
Operating lease payments, per month	$ 1,700
Rent expense	11,634	$ 45,901
Right of use asset			$ 24,257
Impairment of right of use asset	24,257
Operating lease liabilities	20,638		$ 26,028
Operating lease payments	$ 5,390
Lease discount rate	3.90%

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Ending Balance	74,485,067
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning Balance	485,067
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.71
Weighted Average Remaining Contractual Term Years, Beginning Balance	2 years 8 months 15 days
Shares, Granted	78,450,000
Weighted Average Exercise Price, Granted | $ / shares	$ 0.37
Weighted Average Remaining Contractual Term Years Granted	3 years 3 months
Shares, Forfeitures
Weighted Average Exercise Price, Forfeitures | $ / shares
Shares, Expirations
Weighted Average Exercise Price, Expirations | $ / shares
Shares, Exercised	(4,450,000)
Weighted Average Exercise Price, Exercised | $ / shares
Shares, Ending Balance	74,485,067
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 0.38
Weighted Average Remaining Contractual Term Years, Ending Balance	3 years 2 months 26 days

Schedule of Exercise Price of W

Schedule of Exercise Price of Warrants Outstanding and Exercisable (Details)	Mar. 31, 2022$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	74,485,067
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	74,000,000
Exercise Prices | $ / shares	$ 0.37
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	160,108
Exercise Prices | $ / shares	$ 2.05
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	146,667
Exercise Prices | $ / shares	$ 2.67
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	112,001
Exercise Prices | $ / shares	$ 3.30
Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	37,700
Exercise Prices | $ / shares	$ 3.51
Warrant Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	18,174
Exercise Prices | $ / shares	$ 17.25
Warrant Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	10,417
Exercise Prices | $ / shares	$ 30

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Equity [Abstract]
Shares Outstanding, Beginning Balance | shares	853,088
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 6.34
Weighted Average Remaining Contractual Term Years Outstanding, Beginning Balance	6 years 6 months
Shares, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Shares, Forfeitures | shares
Weighted Average Exercise Price, Forfeitures | $ / shares
Shares, Expirations | shares
Weighted Average Exercise Price, Expirations | $ / shares
Shares, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Shares Outstanding, Ending Balance | shares	853,088
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	$ 6.34
Weighted Average Remaining Contractual Term Years Outstanding, Ending Balance	6 years 3 months
Shares Exercisable, Ending Balance | shares	636,259
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	$ 7.41
Weighted Average Remaining Contractual Term Years Outstanding, Ending Balance	4 years 11 months 12 days

Schedule of Exercise Price of O

Schedule of Exercise Price of Options Outstanding and Exercisable (Details) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	853,088	853,088
Options Exercisable (Shares)	636,259
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	41,667
Options Exercisable (Shares)	23,347
Exercise Prices	$ 0.91
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	41,667
Options Exercisable (Shares)	41,667
Exercise Prices	$ 1.48
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	50,000
Options Exercisable (Shares)
Exercise Prices	$ 1.61
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	66,668
Options Exercisable (Shares)	24,996
Exercise Prices	$ 1.76
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	5,000
Options Exercisable (Shares)	5,000
Exercise Prices	$ 1.91
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	41,667
Options Exercisable (Shares)	41,667
Exercise Prices	$ 2.33
Exercise Price Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	1,667
Options Exercisable (Shares)	1,667
Exercise Prices	$ 2.46
Exercise Price Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	16,667
Options Exercisable (Shares)	12,501
Exercise Prices	$ 3.25
Exercise Price Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	152,671
Options Exercisable (Shares)	59,373
Exercise Prices	$ 3.95
Exercise Price Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	208,333
Options Exercisable (Shares)	208,333
Exercise Prices	$ 6
Exercise Price Eleven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	104,167
Options Exercisable (Shares)	104,167
Exercise Prices	$ 12
Exercise Price Twelve [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	10,414
Options Exercisable (Shares)	1,041
Exercise Prices	$ 13.80
Exercise Price Thirteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	112,500
Options Exercisable (Shares)	112,500
Exercise Prices	$ 15

Schedule of Non Vested Restrict

Schedule of Non Vested Restricted Common Stock Activity (Details) - Restricted Common Stock [Member]	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, Non-vested shares, beginning | shares	202,671
Fair value of shares, Non-vested shares, beginning | $ / shares	$ 3.38
Number of shares, Granted | shares
Fair value of shares, Granted | $ / shares
Number of shares, Vested | shares	(152,671)
Fair value of shares, Vested | $ / shares	$ 3.95
Number of shares, Vested | shares
Fair value of shares, Vested | $ / shares
Number of shares, Non-vested shares, ending | shares	50,000
Fair value of shares, Non-vested shares, ending | $ / shares	$ 1.61

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Feb. 23, 2022	Feb. 18, 2022	Feb. 10, 2021	Jan. 28, 2021	Jan. 15, 2021	Jan. 08, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2018
Subsidiary, Sale of Stock [Line Items]
Net proceeds from warrants							$ 1,134,040	$ 3,568,415
Stock options, grants
Stock Options [Member]
Subsidiary, Sale of Stock [Line Items]
Share-Based Payment Arrangement, Expense							$ 85,963	205,772
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Grant date fair value of options granted							662,412
Share-Based Payment Arrangement, Expense							$ 59,906	$ 181,843
Fair value of shares							194,338
Unvested compensation award							$ 41,925
Unvested options, amortized year							2 years 3 months
2018 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Stock options, grants							626,006
Number of restricted stock issued							202,671
Employee Stock Ownership Plan (ESOP), Plan Description									In 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan
Number of stock issued under plan							0	0
Chief Executive Officer [Member]
Subsidiary, Sale of Stock [Line Items]
Stock options, grants								152,671
Grant date fair value of options granted								$ 514,171
Volatility rate								119.00%
Discount rate								0.38%
Expected dividend yield								0.00%
Expected life								6 years
Stock option, exercise price per share								$ 3.95
Chief Executive Officer [Member] | Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of restricted stock issued							152,671
Chief Executive Officer [Member] | Vested One Year [Member]
Subsidiary, Sale of Stock [Line Items]
Number of options vested								50,891
Option vesting period								1 year
Chief Executive Officer [Member] | Vest On Quarterly Basis [Member]
Subsidiary, Sale of Stock [Line Items]
Option vesting period								2 years
Consultant [Member] | Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of restricted stock issued							41,667
Warrants [Member] | Investors [Member]
Subsidiary, Sale of Stock [Line Items]
Net proceeds from warrants							$ 1,334,555
Number of common stock issued							4,450,000
Stock price							$ 0.2999
Unvested Options [Member]
Subsidiary, Sale of Stock [Line Items]
Number of unvested options outstanding							216,829
Number of unvested options outstanding, value							$ 284,388
Unvested options, weighted average remaining life							5 years 2 months 12 days
Closing stock price							$ 0.23
Aggregate intrinsic value of options outstanding							$ 0
Common Stock [Member] | 2018 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares available for grants							837,990
February 2022 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock sold		32,550,000
Proceeds from sale of equity	$ 11,100,000
Sale of stock, proceeds from transaction	9,969,000
Net proceeds from warrants	1,134,000
Cash penalties	$ 20
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1,000
February 2022 Offering [Member] | Series A Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		37,000,000
February 2022 Offering [Member] | Series B Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		37,000,000
February 2022 Offering [Member] | Prefunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,450,000
January 2021 1st ATM Offering [Member] | Sales Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock sold					2,559,834
Sale of stock, proceeds from transaction					$ 9,700,000
January 2021 1st ATM Offering [Member] | Maximum [Member] | Sales Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock sold						$ 10,000,000
January 2021 2nd ATM Offering [Member] | Sales Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock sold			5,048,840
Sale of stock, proceeds from transaction			$ 24,250,000
January 2021 2nd ATM Offering [Member] | Maximum [Member] | Sales Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock sold				$ 25,000,000
January 2021 ATM Offering [Member] | Sales Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, proceeds from transaction							$ 33,663,000
Issuance cost							$ 327,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Jan. 25, 2022$ / shares
Minimum share closing bid price	$ 1
Common Stock [Member]
Minimum share closing bid price	$ 1